On January 17, Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) released the performance forecast for 2021. It is estimated that the net profit attributable to the shareholders of the listed company will be 87-97 million yuan in 2021, an increase of 9.97% – 22.61% over the same period of the previous year.
Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) its main business includes standardized cultivation of medicinal materials, drug production, R & D, sales and pharmaceutical logistics. The company’s main products include Panlong seven tablets, Panlong seven medicinal wine, Jinyin Lidan capsule, kebire Extract Tablets, compound gossypol acetate tablets and API, etc.
The company said that the increase in performance during the reporting period was mainly due to the increase in sales of self-produced products and the increase in revenue from pharmaceutical circulation business.
